ViGenCell’s Immune Cell Therapies To Get A Boost From $85M IPO

IPO Priced At Top Of Stock Price Band

Korean bioventure ViGenCell successfully completes an IPO on the Kosdaq market with strong subscription rates from investors, reflecting the continued keen interest in biopharma shares in South Korea this year.

human cells and veins
ViGenCell Developing Both Autologous And Universal Cell Therapies • Source: Alamy

Immune cell therapy company ViGenCell Inc. has kept the biopharma investment fervor going in South Korea, raising KRW99.4bn ($85m) from an initial public offering on the Kosdaq market.

The stock was priced at the top end of the KRW42,800-52,700 band and the offering was oversubscribed 886.2 times by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from South Korea

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By 

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By 

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.

Tech Convergence, Quality Data Needed To Accelerate Korea’s AI-Powered R&D

 
• By 

AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By 

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

More from Focus On Asia

Chinese Biotech VC/PE Fundings Rise But Still Modest

 

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.